Binod Dhakal, MD

Associate Professor

view physician profile

Locations

Froedtert Hospital
Cancer Center - Froedtert Hospital

Specialties

Hematology
Medical Oncology

Languages

English, Nepali, Hindi

Cancer Center - Froedtert Hospital

(414) 805-0505

Education

MD - Doctor of Medicine

Biography

Binod Dhakal, MD, MS, is Assistant Professor of Medicine, at the Medical College of Wisconsin, Division of Hematology, specializing in multiple myeloma and plasma cell disorders. He graduated from Manipal College of Medical Sciences, Pokhara Nepal in 2004, completed Internal Medicine Residency at Saint Francis Hospital Evanston Illinois, and a fellowship in hematology/oncology at the Medical College of Wisconsin, where he also served as a Chief Fellow. Prior to joining the fellowship, he was Assistant Professor of Medicine at the Medical College in Wisconsin in the Division of General Internal Medicine. He has authored numerous publications, including journal articles, meeting abstracts and book chapters. He has also won several awards during his fellowship which include the American Society of Clinical Oncology (ASCO) Merit Award; Medical College of Wisconsin Affiliated Hospitals (MCWAH) research award; Central Society for Clinical and Translational Research (CSCTR) best oral abstract and travel trainee award; American Society for Blood and Marrow Transplantation (ASBMT) clinical research training course; and, Outstanding Medical School Teacher award. Additionally, he was the recipient of the Mazie Froedtert Willms and Sue Froedtert Cancer Scholarship, and obtained his Master’s Degree in Clinical and Translational Science.

Research Interests

Dr. Dhakal's current research interests focus on novel drug treatments for patients with multiple myeloma and related plasma cell disorders by designing and conducting early phase clinical trials.

Impact of Chronic Kidney Disease and Acute Kidney Injury on Safety and Outcomes of CAR T-Cell Therapy in Lymphoma Patients.

(Ahmed G, Bhasin-Chhabra B, Szabo A, Shah NN, Longo W, Dhakal B, Chhabra S, D'Souza A, Fenske TS, Hamadani M.) Clin Lymphoma Myeloma Leuk. 2022 Jul 18 PMID: 35934632 SCOPUS ID: 2-s2.0-85135507182 08/08/2022
Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma.

(Kansagra A, Dispenzieri A, Fraser R, Estrada-Merly N, Sidana S, Nishihori T, Hansen DK, Anderson LD Jr., Banerjee R, Bumma N, Dhakal B, Khouri J, Landau H, Lee C, Mian H, Nathan S, Savani B, Kumar S, Qazilbash M, Shah N, D'Souza A.) Blood Adv. 2022 07 12;6(13):3991-3995 PMID: 35507742 PMCID: PMC9278304 SCOPUS ID: 2-s2.0-85134538302 05/05/2022
Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience.

(Mohan M, Becnel MR, Shah UA, Dong H, Gundarlapalli S, Peterson T, Orozco JS, Horowitz S, Chhabra S, Dhakal B, Thanendrarajan S, Radhakrishnan SV, Al Hadidi S, Tan C, Mailankody S, Hultcrantz M, Korde N, Hassoun H, Lesokhin AM, Thomas SK, Patel KK, Manasanch EE, Weber DM, Szabo A, Kaufman GP, Lee HC, Zangari M, van Rhee F, Usmani SZ, D'Souza A, Orlowski RZ, Schinke C.) Am J Hematol. 2022 Jul;97(7):E276-E280 PMID: 35472167 SCOPUS ID: 2-s2.0-85129190892 04/27/2022
Shorter Interval between Treatment and COVID Immunization Is Associated With Poor Seroconversion in Patients with Hematological Malignancies.

(Mohan M, Nagavally S, Shah N NN, Michaelis L, Chhabra S, Souza AD, Abedin S, Runaas L, Guru Murthy GS, Longo W, Hamadani M, Dhakal B, Hari P, Fenske TS.) Clin Lymphoma Myeloma Leuk. 2022 Jul;22(7):e495-e497 PMID: 35148976 PMCID: PMC8767926 SCOPUS ID: 2-s2.0-85132179962 02/13/2022
Impact of autologous hematopoietic cell transplantation on disease burden quantified by next-generation sequencing in multiple myeloma treated with quadruplet therapy.

(Bal S, Dhakal B, Silbermann RW, Schmidt TM, Dholaria B, Giri S, Chhabra S, Medvedova E, Godby KN, D'Souza A, Hall AC, Hardwick P, Omel J, Cornell RF, Hari P, Callander NS, Costa LJ.) Am J Hematol. 2022 Jun 22 PMID: 35731911 SCOPUS ID: 2-s2.0-85133435905 06/23/2022
ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma.

(Dhakal B, Shah N, Kansagra A, Kumar A, Lonial S, Garfall A, Cowan A, Poudyal BS, Costello C, Gay F, Cook G, Quach H, Einsele H, Schriber J, Hou J, Costa L, Aljurf M, Chaudhry M, Beksac M, Prince M, Mohty M, Janakiram M, Callander N, Biran N, Malhotra P, Otero PR, Moreau P, Abonour R, Iftikhar R, Silberman R, Mailankody S, Gregory T, Lin Y, Carpenter P, Hamadani M, Usmani S, Kumar S.) Transplant Cell Ther. 2022 06;28(6):284-293 PMID: 35306217 SCOPUS ID: 2-s2.0-85128352615 03/21/2022
Socioeconomic disadvantage contributes to ethnic disparities in multiple myeloma survival: a matched cohort study.

(Buradagunta CS, Garacci Z, D'Souza A, Dhakal B, Devata S, Janz S, Thrift AP, Hari P, Stolley M, Dong J.) Blood Cancer J. 2022 05 25;12(5):82 PMID: 35614050 PMCID: PMC9132975 SCOPUS ID: 2-s2.0-85130720530 05/26/2022
Efficacy of a third SARS-CoV-2 mRNA vaccine dose among hematopoietic cell transplantation, CAR TA cell, and BiTE recipients.

(Abid MB, Rubin M, Ledeboer N, Szabo A, Longo W, Mohan M, Shah NN, Fenske TS, Abedin S, Runaas L, D'Souza A, Chhabra S, Dhakal B, Hamadani M.) Cancer Cell. 2022 04 11;40(4):340-342 PMID: 35202585 PMCID: PMC8864440 SCOPUS ID: 2-s2.0-85127542763 02/25/2022
Critical Role for Cap-Independent c-MYC Translation in Progression of Multiple Myeloma.

(Shi Y, Sun F, Cheng Y, Holmes B, Dhakal B, Gera JF, Janz S, Lichtenstein A.) Mol Cancer Ther. 2022 04 01;21(4):502-510 PMID: 35086951 PMCID: PMC8983490 SCOPUS ID: 2-s2.0-85128145497 01/29/2022
Rap1A, Rap1B, and I?-Adrenergic Signaling in Autologous HCT: A Randomized Controlled Trial of Propranolol.

(Johnson AK, Lorimer EL, Szabo A, Wu R, Shah NN, D'Souza A, Chhabra S, Hamadani M, Dhakal B, Hari P, Rao S, Carlson K, Williams CL, Knight JM.) Yale J Biol Med. 2022 03;95(1):45-56 PMID: 35370486 PMCID: PMC8961707 SCOPUS ID: 2-s2.0-85127524780 04/05/2022
Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study.

(Dong J, Garacci Z, Buradagunta CS, D'Souza A, Mohan M, Cunningham A, Janz S, Dhakal B, Thrift AP, Hari P.) Blood Cancer J. 2022 02 24;12(2):34 PMID: 35210395 PMCID: PMC8873507 SCOPUS ID: 2-s2.0-85125303734 02/26/2022
Assessment of Molecular Residual Disease Using Circulating Tumor DNA to Identify Multiple Myeloma Patients at High Risk of Relapse.

(Dhakal B, Sharma S, Balcioglu M, Shchegrova S, Malhotra M, Zimmermann B, Billings PR, Harrington A, Sethi H, Aleshin A, Hari PN.) Front Oncol. 2022;12:786451 PMID: 35186734 PMCID: PMC8848740 SCOPUS ID: 2-s2.0-85124893548 02/22/2022